Vascular α1-Adrenergic Receptor Responsiveness in Masked Hypertension.

American Journal of Hypertension
Yuichiro YanoAndrew Sherwood

Abstract

Masked hypertension (nonhypertensive in the clinic setting but hypertensive outside the clinic during wakefulness) is characterized by increased blood pressure in response to physical and emotional stressors that activate the sympathetic nervous system (SNS). However, no studies have assessed vascular reactivity to a pharmacological SNS challenge in individuals with masked hypertension. We analyzed data from 161 adults aged 25 to 45 years (mean ± standard deviation age 33 ± 6 years; 48% were African American and 43% were female). Participants completed ambulatory blood pressure monitoring, and a standardized α 1-adrenergic agonist phenylephrine test that determines the dose of phenylephrine required to increase a participant's mean arterial pressure by 25 mm Hg (PD25). Twenty-one participants were considered to have masked hypertension (clinic systolic blood pressure (SBP) <140 and diastolic blood pressure (DBP) <90 mm Hg but awake SBP ≥135 or DBP ≥85 mm Hg), 28 had sustained hypertension (clinic SBP ≥140 or DBP ≥90 mm Hg and awake SBP ≥135 or DBP ≥85 mm Hg), and 106 had sustained normotension (clinic SBP <140 and DBP <90 mm Hg and awake SBP <135 and DBP <85 mm Hg). After multivariable adjustment, the mean (±SE) PD25 was less i...Continue Reading

References

Sep 1, 1987·The Journal of Clinical Investigation·B EganS Julius
Jul 1, 1974·The Journal of Clinical Investigation·C E MartinJ J Leonard
Feb 1, 1982·Circulation·T A KotchenJ M Kotchen
Feb 14, 1995·European Journal of Pharmacology·H GurdalM D Johnson
Jul 1, 1996·Hypertension·N L BenowitzM Cheitlin
Jun 9, 2001·Trends in Endocrinology and Metabolism : TEM·K C Lee, W Lee Kraus
Feb 28, 2002·American Journal of Hypertension·Andrew SherwoodAlan L Hinderliter
Sep 7, 2002·Life Sciences·Akito TanoueGozoh Tsujimoto
Feb 25, 2003·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·Marc P Kaufman, Shawn G Hayes
Jan 1, 2004·American Journal of Hypertension·Alan L HinderliterAndrew Sherwood
Jul 11, 2007·Hypertension·Guido GrassiGiuseppe Mancia
Dec 21, 2007·The Annals of Pharmacotherapy·Jane R Mort, Heather R Kruse
Aug 14, 2008·Journal of Hypertension·Guillaume BobriePierre-François Plouin
Oct 29, 2009·Cellular and Molecular Life Sciences : CMLS·James R Docherty
Nov 26, 2010·Clinical and Experimental Hypertension : CHE·Mehmet KayrakHasan Gok
Dec 22, 2010·The Journal of Physiology·Rudi Vennekens
Apr 1, 2011·Blood Pressure·Martin G SchultzJames E Sharman
Apr 29, 2011·American Journal of Hypertension·James E SharmanThomas H Marwick
Nov 18, 2011·American Journal of Hypertension·Kageumi TakenoHirotaka Watada
Nov 6, 2013·Nature Reviews. Nephrology·Kazuomi Kario
Sep 1, 1996·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·P J GreenJ Suls
Dec 19, 2013·Frontiers in Physiology·Dario LeoscoDomenico Bonaduce
Aug 20, 2014·Hypertension·Kei AsayamaUNKNOWN International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators
Jan 23, 2015·Blood Pressure·Cesare CuspidiGiuseppe Mancia

❮ Previous
Next ❯

Citations

Mar 18, 2020·American Journal of Hypertension·Raj Padwal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.